Seagen (Seagen) Total Current Liabilities : $955 Mil (As of Sep. 2023)

View and export this data going back to 2001. Start your Free Trial

What is Seagen Total Current Liabilities?

Total current liabilities includes Accounts Payable & Accrued Expense, Short-Term Debt & Capital Lease Obligation, Other Current Liabilities, and Current Deferred Liabilities. Seagen's total current liabilities for the quarter that ended in Sep. 2023 was $955

Seagen Total Current Liabilities Historical Data

The historical data trend for Seagen's Total Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Seagen Total Current Liabilities Chart

Seagen Annual Data

Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22

Total Current Liabilities

Get a 7-Day Free Trial 225.07 259.36 388.14 568.85 818.40

Seagen Quarterly Data

Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23

Total Current Liabilities Get a 7-Day Free Trial 726.00 818.40 713.23 762.90 954.72

Seagen Total Current Liabilities Calculation

Total Current Liabilities is the total amount of liabilities that the company needs to pay over the next 12 months.

Seagen's Total Current Liabilities for the fiscal year that ended in Dec. 2022 is calculated as

Total Current Liabilities = Accounts Payable & Accrued Expense + Short-Term Debt & Capital Lease Obligation

= 642.898 + 0

+ Other Current Liabilities + Current Deferred Liabilities

= 175.506 + 0

= 818

Seagen's Total Current Liabilities for the quarter that ended in Sep. 2023 is calculated as

Total Current Liabilities = Accounts Payable & Accrued Expense + Short-Term Debt & Capital Lease Obligation

= 742.274 + 0

+ Other Current Liabilities + Current Deferred Liabilities

= 212.442 + 0

= 955

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The increase of Total Current Liabilities of a company is not necessarily a bad thing. This may conserve the company's cash and contribute positively to cash flow.

Total Current Liabilities is linked to Total Current Assets through the Current Ratio and Working Capital. The Current Ratio is equal to dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations. Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term.

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

Seagen Total Current Liabilities Related Terms
Thank you for viewing the detailed overview of Seagen's Total Current Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Seagen (Seagen) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Seagen Inc (NAS:SGEN) » Definitions » Total Current Liabilities

Comparable Companies

MRNA BNTX ALNY BGNE BMRN INCY RPRX TECH KRTX LEGN OCSE:NOVO B VRTX REGN ASX:CSL XKRX:207940 XKRX:068270 XBRU:ARGX OCSE:GMAB SZSE:300122 XBRU:UCB

Traded in Other Exchanges

N/A

Address

21823 - 30th Drive South East, Bothell, WA, USA, 98021

Website

https://www.seagen.com

Seagen (formerly known as Seattle Genetics) is a biotech firm that develops and commercializes therapies to treat cancers. Seagen's therapies are based on antibody-drug conjugate technology that utilizes the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells. The company's lead product, Adcetris, has received approval for six indications to treat Hodgkin lymphoma and T-cell lymphoma. Other approved products include Padcev for bladder cancer, Tukysa for breast cancer, and Tivdak for cervical cancer. The company has several other oncology programs in pivotal trials. Seagen also licenses its antibody-drug conjugate technology to several leading biotechnology and pharmaceutical companies.

Executives

David R Epstein director, officer: Chief Executive Officer INTERNATIONAL FLAVORS & FRAGRANCES INC., 521 W. 57TH STREET, NEW YORK NY 10019

Vaughn B Himes officer: See Remarks C/O SEATTLE GENETICS, INC., 21823 30TH DRIVE SE, BOTHELL WA 98021

Charles R Romp officer: EVP, Commercial 21823 30TH DRIVE SE, BOTHELL WA 98021

Roger D Dansey officer: See Remarks 21823 30TH DRIVE SE, BOTHELL WA 98021

Jean I Liu officer: GC & EVP, Legal Affairs 21823 30TH DRIVE SE, BOTHELL WA 98021

Todd E Simpson officer: Chief Financial Officer

Daniel G Welch director 4611 UNIVERSITY DR, 4 UNIVERSITY PLACE, DURHAM NC 27707

David W Gryska director 749 N MARY AVE, SUNNYVALE CA 94085

Sandra M Swain director 21823 30TH DRIVE SE, BOTHELL WA 98021

Ted W Love director C/O GLOBAL BLOOD THERAPEUTICS, INC., 400 EAST JAMIE COURT, SUITE 101, SOUTH SAN FRANCISCO CA 94080

Clay B Siegall director, officer: President and CEO 21823 30TH DR SE, BOTHELL WA 98021

Baker Bros. Advisors Lp director, 10 percent owner 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014

Felix Baker director, 10 percent owner BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014

Julian Baker director, 10 percent owner BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014

Baker Brothers Life Sciences Lp director, 10 percent owner 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014

Seagen (Seagen) Headlines

From GuruFocus

Seagen to Highlight Overall Survival Data for PADCEV� and TIVDAK� during Presidential Symposium at ESMO Congress 2023
By Business Wire • 10-16-2023

Seagen to Highlight Data From Oncology Portfolio and Pipeline at the 2023 American Society of Clinical Oncology Annual Meeting
By Business Wire Business Wire • 04-26-2023

Seagen Second Quarter 2023 Financial Results Demonstrate Exceptional Commercial Performance Driving Record Product Sales with Strong Growth and Momentum
By Business Wire • 08-02-2023

Insider Sell: Seagen Inc's CTO Vaughn Himes Sells 8,785 Shares
By GuruFocus Research • 09-09-2023

Seagen to Report Third Quarter 2023 Financial Results on November 1, 2023
By Business Wire • 10-12-2023

Phase 3 Trial of ADCETRIS� (brentuximab vedotin) with Modified Chemo Regimen Shows Non-Inferiority with Unprecedented 3-Year Progression Free Survival of 94.9% vs Less Tolerable International Standard of Care in Advanced Classical Hodgkin Lymphoma
By Business Wire Business Wire • 06-20-2023

Seagen Inc (SGEN) Reports 33% Increase in 3Q23 Net Product Sales
By GuruFocus Research • 11-01-2023

Seagen to Present at the Cowen 43rd Annual Health Care Conference
By Business Wire Business Wire • 02-27-2023

Seagen to Highlight Research in Urothelial Cancer at the 2023 American Society of Clinical Oncology Genitourinary Cancers Symposium
By Business Wire Business Wire • 02-13-2023

Six-Year Overall Survival Results Added to U.S. Prescribing Information for ADCETRIS� (brentuximab vedotin) as First-Line Treatment for Advanced Hodgkin Lymphoma
By Business Wire Business Wire • 06-15-2023

Seagen Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Total Current Liabilities	Get a 7-Day Free Trial															726.00	818.40	713.23	762.90	954.72

Total Current Liabilities	=	Accounts Payable & Accrued Expense	+	Short-Term Debt & Capital Lease Obligation
	=	642.898	+	0
	+	Other Current Liabilities	+	Current Deferred Liabilities
	=	175.506	+	0
	=	818

David R Epstein	director, officer: Chief Executive Officer	INTERNATIONAL FLAVORS & FRAGRANCES INC., 521 W. 57TH STREET, NEW YORK NY 10019
Vaughn B Himes	officer: See Remarks	C/O SEATTLE GENETICS, INC., 21823 30TH DRIVE SE, BOTHELL WA 98021
Charles R Romp	officer: EVP, Commercial	21823 30TH DRIVE SE, BOTHELL WA 98021
Roger D Dansey	officer: See Remarks	21823 30TH DRIVE SE, BOTHELL WA 98021
Jean I Liu	officer: GC & EVP, Legal Affairs	21823 30TH DRIVE SE, BOTHELL WA 98021
Todd E Simpson	officer: Chief Financial Officer
Daniel G Welch	director	4611 UNIVERSITY DR, 4 UNIVERSITY PLACE, DURHAM NC 27707
David W Gryska	director	749 N MARY AVE, SUNNYVALE CA 94085
Sandra M Swain	director	21823 30TH DRIVE SE, BOTHELL WA 98021
Ted W Love	director	C/O GLOBAL BLOOD THERAPEUTICS, INC., 400 EAST JAMIE COURT, SUITE 101, SOUTH SAN FRANCISCO CA 94080
Clay B Siegall	director, officer: President and CEO	21823 30TH DR SE, BOTHELL WA 98021
Baker Bros. Advisors Lp	director, 10 percent owner	860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Felix Baker	director, 10 percent owner	BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014
Julian Baker	director, 10 percent owner	BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014
Baker Brothers Life Sciences Lp	director, 10 percent owner	860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014